After leading one of the early pioneers in customized cancer therapies using patient cells for CAR-T, the founding execs at Sana Biotechnology are now nailing down the IP for a new generation of off-the-shelf cell therapies that they believe can have built-in protection against an immune response. And they’re throwing in some open access tech on gene editing to boot.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,900+ biopharma pros who read Endpoints News by email every day.Free Subscription